We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
89bio Inc
5 own
6 watching
Current Price
$6.27
$-0.02
(-0.24%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
802.64M
52-Week High
16.63000
52-Week Low
6.15200
Average Volume
2.1M
Dividend Yield
--
P/E Ratio
--
Market Capitalization802.64M52-Week High16.6300052-Week Low6.15200Average Volume2.1MDividend Yield--P/E Ratio--What does the 89bio Inc do?
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
Read More
How much money does 89bio Inc make?
News & Events about 89bio Inc.
Globe Newswire
1 year ago
Published data showed consistent and significant reductions in triglycerides, atherogenic lipoproteins and liver fat, and pegozafermins favorable safety and tolerability profile SHTG Phase 3 ENTRUST trial initiated in May 2023 SAN FRANCISCO, June 24, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ...
Globe Newswire
1 year ago
ENLIVEN results demonstrated that treatment with pegozafermin 30mg weekly and 44mg every-two-week doses resulted in statistically significant changes on both primary histology endpoints New data showed pegozafermin resulted in significant benefit across several key sub populations of NASH patients, ...
Ticker Report
1 year ago
89bio, Inc. (NASDAQ:ETNB Get Rating) CEO Rohan Palekar sold 15,000 shares of the firms stock in a transaction that occurred on Monday, June 5th. The shares were sold at an average price of $20.00, for a total transaction of $300,000.00. Following the transaction, the chief executive ...
Ticker Report
1 year ago
89bio, Inc. (NASDAQ:ETNB Get Rating) Director Michael R. Hayden bought 61,538 shares of the stock in a transaction that occurred on Tuesday, March 28th. The stock was acquired at an average price of $16.15 per share, for a total transaction of $993,838.70. Following the acquisition, the ...
Zolmax
1 year ago
89bio, Inc. (NASDAQ:ETNB Get Rating) Stock analysts at HC Wainwright increased their Q1 2023 EPS estimates for 89bio in a research report issued to clients and investors on Monday, March 20th. HC Wainwright analyst E. Arce now expects that the company will earn ($0.40) per share for the quarter, up ...
Frequently Asked Questions
Frequently Asked Questions
What is 89bio Inc share price today?
Can Indians buy 89bio Inc shares?
How can I buy 89bio Inc shares from India?
Can Fractional shares of 89bio Inc be purchased?
What are the documents required to start investing in 89bio Inc stocks?
What is today’s traded volume of 89bio Inc?
What is today’s market capitalisation of 89bio Inc?
What is the 52-Week High and Low Range of 89bio Inc?
What percentage is 89bio Inc down from its 52-Week High?
What percentage is 89bio Inc up from its 52-Week Low?
Current Price
$6.27
$-0.02
(-0.24%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.